428 assets in Triple-Negative Breast Carcinoma

Therapeutic assets addressing Triple-Negative Breast Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
tqb2102 Triple-Negative Breast Carcinoma	Fudan University	P2	CCC (53)
tqb2868 Triple-Negative Breast Carcinoma	Fudan University	P2	CCC (53)
Xiaopi Decoction Triple-Negative Breast Carcinoma	Zhiyu Wang	P2	CCC (53)
Yb-1 Triple-Negative Breast Carcinoma	University of Washington	P2	CCC (53)
Adagloxad Simolenin Triple-Negative Breast Carcinoma	OBI Pharma, Inc	P3	CCC (52)
Bortezomib Triple-Negative Breast Carcinoma	Andrew Hantel, MD	P1	CCC (52)
Eribulin Mesilate Triple-Negative Breast Carcinoma	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	P3	CCC (52)
fda018-adc Triple-Negative Breast Carcinoma	Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.	P3	CCC (52)
Flavone, 3,3',4',5,7-Pentahydroxy- Triple-Negative Breast Carcinoma	Fudan University	P2	CCC (52)
Ganetespib Triple-Negative Breast Carcinoma	Synta Pharmaceuticals Corp.	P2	CCC (52)
Goserelin Triple-Negative Breast Carcinoma	National Taiwan University Hospital	P2	CCC (52)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer Triple-Negative Breast Carcinoma	OncoNano Medicine, Inc.	P2	CCC (52)
Jskn016 Triple-Negative Breast Carcinoma	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	P3	CCC (52)
Moxifloxacin Triple-Negative Breast Carcinoma	Sun Yat-Sen University Cancer Center	P3	CCC (52)
Nanosomal Docetaxel Lipid Suspension Triple-Negative Breast Carcinoma	Jina Pharmaceuticals Inc.	P3	CCC (52)
Saponin-Based Immunoadjuvant Obi-821 Triple-Negative Breast Carcinoma	OBI Pharma, Inc	P3	CCC (52)
Tuvonralimab Triple-Negative Breast Carcinoma	Harbin Medical University	P2/3	CCC (52)
arx788 Triple-Negative Breast Carcinoma	Laura Huppert, MD, BA	P2	CCC (51)
azd6738 Triple-Negative Breast Carcinoma	Institute of Cancer Research, United Kingdom	P2	CCC (51)
b1962 Triple-Negative Breast Carcinoma	Tasly Biopharmaceuticals Co., Ltd.	P2	CCC (51)
Dan-222 Triple-Negative Breast Carcinoma	QuantumLeap Healthcare Collaborative	P2	CCC (51)
Dostarlimab Triple-Negative Breast Carcinoma	Massachusetts General Hospital	P2	CCC (51)
Encequidar Triple-Negative Breast Carcinoma	QuantumLeap Healthcare Collaborative	P2	CCC (51)
Fianlimab Triple-Negative Breast Carcinoma	QuantumLeap Healthcare Collaborative	P2	CCC (51)
Fluoromisonidazole Triple-Negative Breast Carcinoma	University of Alabama at Birmingham	P2	CCC (51)
Girentuximab Triple-Negative Breast Carcinoma	Institut Cancerologie de l'Ouest	P2	CCC (51)
Gsk 5733584 Triple-Negative Breast Carcinoma	QuantumLeap Healthcare Collaborative	P2	CCC (51)
Immunoglobulin G1 [300-Alanine], Anti-(Human Cd73 Antigen) (Human-Mus Musculus Monoclonal Tj004309 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal Tj004309 ?-Chain, Dimer Triple-Negative Breast Carcinoma	I-Mab Biopharma US Limited	P2	CCC (51)
Immunoglobulin G4, Anti-(Human Colony-Stimulating Factor 1 Receptor) (Human-Rattus Norvegicus Monoclonal Sndx-6352 .Gamma.4-Chain), Disulfide With Human-Rattus Norvegicus Monoclonal Sndx-6352 .Kappa.-Chain, Dimer Triple-Negative Breast Carcinoma	Stephen Shiao	P2	CCC (51)
Inavolisib Triple-Negative Breast Carcinoma	Hu Hai	P2	CCC (51)
Ivarmacitinib Triple-Negative Breast Carcinoma	Fudan University	P2	CCC (51)
jk-1201i Triple-Negative Breast Carcinoma	JenKem Technology Co., Ltd.	P2	CCC (51)
Lasofoxifene Triple-Negative Breast Carcinoma	QuantumLeap Healthcare Collaborative	P2	CCC (51)
Loperamide Triple-Negative Breast Carcinoma	MedSIR	P2	CCC (51)
Mifepristone Triple-Negative Breast Carcinoma	Indiana University	P2	CCC (51)
Mirabegron Triple-Negative Breast Carcinoma	Zhejiang Provincial People's Hospital	P2	CCC (51)
N-Desmethyl-4-Hydroxytamoxifen Triple-Negative Breast Carcinoma	QuantumLeap Healthcare Collaborative	P2	CCC (51)
PCS6422 Triple-Negative Breast Carcinoma	Processa Pharmaceuticals	P2	CCC (51)
Pexidartinib Triple-Negative Breast Carcinoma	QuantumLeap Healthcare Collaborative	P2	CCC (51)
sc-101 Triple-Negative Breast Carcinoma	Tianjin ConjuStar Biologics Co., Ltd.	P2	CCC (51)
Shr-A2009 Triple-Negative Breast Carcinoma	Fudan University	P2	CCC (51)
Shr-A2102 Triple-Negative Breast Carcinoma	Henan Cancer Hospital	P2	CCC (51)
Tagitanlimab Triple-Negative Breast Carcinoma	Tianjin Medical University Cancer Institute and Hospital	P2	CCC (51)
Tenalisib Triple-Negative Breast Carcinoma	Rhizen Pharmaceuticals SA	P2	CCC (51)
Tifcemalimab Triple-Negative Breast Carcinoma	Shengjing Hospital	P2	CCC (51)
Tirelizumab Triple-Negative Breast Carcinoma	Huihua Xiong	P2	CCC (51)
Trebananib Triple-Negative Breast Carcinoma	QuantumLeap Healthcare Collaborative	P2	CCC (51)
Tretinoin Triple-Negative Breast Carcinoma	Fudan University	P2	CCC (51)
Vepdegestrant Triple-Negative Breast Carcinoma	QuantumLeap Healthcare Collaborative	P2	CCC (51)
vv1 Triple-Negative Breast Carcinoma	QuantumLeap Healthcare Collaborative	P2	CCC (51)

Showing 151 to 200 of 428 assets

PreviousPage 4 of 9Next